Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)
OncologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Epigenetics
- Publicado em
- 12 abr 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)
Lynn Symonds, Ming Yu, Yuhong Zhang, Fang-Shu Ou, Tyler J Zemla, Kelly Carter, Monica Bertagnolli, Federico Innocenti, Linda Jw Bosch, Gerrit A Meijer et al.
Descritores MeSH
- Leukemia
- Adenocarcinoma
- Colonic Neoplasms
- Fluorouracil
- Humans
- Neoplasm Staging
- Prognosis
- Biomarkers
- Proto-Oncogene Proteins p21(ras)
- Chemotherapy, Adjuvant
Veja também
Estudos relacionados
- Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population
- Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis
- Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer